Overexpression of NDRG2 promotes the therapeutic effect of pazopanib on ovarian cancer

References

• Brett MR, Jennifer BP, Thomas AS. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14:9–32.
   PubMed Web of Science ®Google Scholar
• Ivo MH, Christina F, Philipp H, et al. The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. Arch Gynecol Obstet. 2016;293:695–700.
   PubMed Web of Science ®Google Scholar
• Teplinsky E, Herzog TJ. The efficacy of trabectedin in treating ovarian cancer. Expert Opin Pharmacother. 2017;18(3):313–323.
   PubMed Web of Science ®Google Scholar
• Rakesh K, Victoria BK, Sharon KR, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007;6:2012–2021.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430–1437.
   PubMed Web of Science ®Google Scholar
• van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–1886.
   PubMed Web of Science ®Google Scholar
• McLachlan J, Banerjee S. Pazopanib in ovarian cancer. Expert Rev Anticancer Ther. 2015;15(9):995–1005.
   PubMed Web of Science ®Google Scholar
• Ma J, Liu WC, Guo H, et al. N-myc downstream-regulated gene 2 expression is associated with glucose transport and correlated with prognosis in breast carcinoma. Breast Cancer Res. 2014;16(2):R27.
   PubMed Web of Science ®Google Scholar
• Li Y, Liu C, Hou W, et al. Retrograde ductal administration of the adenovirus-mediated NDRG2 gene leads to improved sialaden hypofunction in estrogen-deficient rats. Mol Ther. 2014;22(5):908–918.
   PubMed Web of Science ®Google Scholar
• Shen L, Liu X, Hou W, et al. NDRG2 is highly expressed in pancreatic beta cells and involved in protection against lipotoxicity. Cell Mol Life Sci. 2010;67(8):1371–1381.
   PubMed Web of Science ®Google Scholar
• Xu XB, Melanie SH, Tan XY, et al. CRISPR/Cas derivatives as novel gene modulating tools: possibilities and in vivo applications. Int J Mol Sci. 2020;21(9):3038.
   PubMed Web of Science ®Google Scholar
• Zhang LL, Wang HA, Li W, et al. Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis. Oncotarget. 2017;8(2):3289–3303.
   PubMedGoogle Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Rebecca LS, Kimberly DM. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.
   PubMed Web of Science ®Google Scholar
• Hideaki N, Robert V, Gillian M. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562–573.
   PubMed Web of Science ®Google Scholar
• Zhu J, Hoop CL, Case DA, et al. Cryptic binding sites become accessible through surface reconstruction of the type I collagen fibril. Sci Rep. 2018;8(1):16646.
   PubMedGoogle Scholar
• Gersh I, Catchpole HR. The organization of ground substance and basement membrane and its significance in tissue injury disease and growth. Am J Anat. 1949;85(3):457–521.
   PubMedGoogle Scholar
• Rajeshwar PV, Corwin H. Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. Bioorg Med Chem. 2007;15:2223–2268.
   PubMed Web of Science ®Google Scholar
• Takashi S, Takeaki S, Yutaka N, et al. Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol Oncol. 2004;92:47–56.
   PubMed Web of Science ®Google Scholar
• Gohji K, Fujimoto N, Hara I, et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer. 1998;79(1):96–101.
   PubMed Web of Science ®Google Scholar
• Stetler-Stevenson WG. The role of matrix metalloproteinases in tumor invasion, metastasis and angiogenesis. Surg Oncol Clin N Am. 2001;10(2):383–392.
   PubMedGoogle Scholar
• Baker A, Edwards D, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci. 2002;115(19):3719–3727.
   PubMed Web of Science ®Google Scholar
• Murphy G. Tissue inhibitors of metalloproteinases. Genome Biol. 2011;12(11):233.
   PubMed Web of Science ®Google Scholar
• David P, Fan Y, Trinh N, et al. Matrisome-associated gene expression patterns correlating with TIMP2 in cancer. Sci Rep. 2019;9(1):20142.
   PubMedGoogle Scholar
• Wioletta P, Katarzyna BP, Józef K. Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: an immunohistochemical study. Otolaryngol Pol. 2016;70:32–43.
   PubMedGoogle Scholar
• Braicu EI, Fotopoulou C, Chekerov R, et al. Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy. Cytokine. 2013;61(3):755–758.
   PubMed Web of Science ®Google Scholar
• Elena IB, Khayal G, Rolf R, et al. Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to adjuvant radiochemotherapy in patients with primary cervical cancer–results of a companion protocol of the randomized NOGGO-AGO phase III clinical trial. Anticancer Res. 2014;34:385–391.
   PubMed Web of Science ®Google Scholar
• Black RA. TIMP3 checks inflammation. Nat Genet. 2004;36(9):934–935.
   PubMed Web of Science ®Google Scholar
• Whiteside EJ, Jackson MM, Herington AC, et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-3 are key regulators of extracellular matrix degradation by mouse embryos. Biol Reprod. 2001;64(5):1331–1337.
   PubMed Web of Science ®Google Scholar
• Staton CA, Kumar I, Reed MWR, et al. Neuropilins in physiological and pathological angiogenesis. J Pathol. 2007;212(3):237–248.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380(6573):439–442.
   PubMed Web of Science ®Google Scholar
• Lieu CH, Tran H, Jiang ZQ, et al. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One. 2013;8(10):e77117.
   PubMed Web of Science ®Google Scholar
• Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006;6(7):506–520.
   PubMed Web of Science ®Google Scholar
• Pickup M, Novitskiy S, Moses HL. The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer. 2013;13(11):788–799.
   PubMed Web of Science ®Google Scholar
• Komuro A, Yashiro M, Iwata C, et al. Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor β signaling. J Natl Cancer Inst. 2009;101(8):592–604.
   PubMedGoogle Scholar
• Kandel J, Bossy-Wetzel E, Radvanyi F, et al. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell. 1991;66(6):1095–1104.
   PubMed Web of Science ®Google Scholar
• Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med. 1997;3(8):887–893.
   PubMed Web of Science ®Google Scholar
• Presta M, Dell’Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005;16(2):159–178.
   PubMed Web of Science ®Google Scholar
• Ahmad A, Wang Z, Kong D, et al. Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-κB signaling pathways. Breast Cancer Res Treat. 2011;126(1):15–25.
   PubMed Web of Science ®Google Scholar
• Wang Z, Kong D, Banerjee S, et al. Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling. Cancer Res. 2007;67(23):11377–11385.
   PubMed Web of Science ®Google Scholar
• Zhao L, Zhang C, Liao G, et al. RNAi-mediated inhibition of PDGF-D leads to decreased cell growth, invasion and angiogenesis in the SGC-7901 gastric cancer xenograft model. Cancer Biol Ther. 2010;9(1):42–48.
   PubMed Web of Science ®Google Scholar
• Liu J, Liao S, Huang Y, et al. PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer. Clin Cancer Res. 2011;17(11):3638–3648.
   PubMed Web of Science ®Google Scholar
• Xu L, Tong R, Cochran DM, et al. Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res. 2005;65(13):5711–5719.
   PubMed Web of Science ®Google Scholar
• Shi Y. Caspase activation: revisiting the induced proximity model. Cell. 2004;117(7):855–858.
   PubMed Web of Science ®Google Scholar
• Qin H, Srinivasula SM, Wu G, et al. Structural basis of procaspase-9 recruitment by the apoptotic protease-activating factor 1. Nature. 1999;399(6736):549–557.
   PubMed Web of Science ®Google Scholar
• Kiechle T, Dedeoglu A, Kubilus J, et al. Cytochrome C and caspase-9 expression in Huntington’s disease. Neuromolecular Med. 2002;1(3):183–195.
   PubMed Web of Science ®Google Scholar
• Slee EA, Harte MT, Kluck RM, et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol. 1999;144(2):281–292.
   PubMed Web of Science ®Google Scholar
• Ichijo H, Nishida E, Irie K, et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science. 1997;275(5296):90–94.
   PubMed Web of Science ®Google Scholar
• Tesch GH, Ma FY, Han Y, et al. ASK1 inhibitor halts progression of diabetic nephropathy in Nos3-Deficient Mice. Diabetes. 2015;64(11):3903–3913.
   PubMed Web of Science ®Google Scholar
• Ma FY, Tesch GH, Nikolic-Paterson DJ. ASK1/p38 signaling in renal tubular epithelial cells promotes renal fibrosis in the mouse obstructed kidney. Am J Physiol Renal Physiol. 2014;307(11):F1263–F1273.
   PubMed Web of Science ®Google Scholar
• Androutsopoulos VP, Spandidos DA. Anticancer pyridines induce G2/M arrest and apoptosis via p53 and JNK upregulation in liver and breast cancer cells. Oncol Rep. 2018;39(2):519–524.
   PubMed Web of Science ®Google Scholar
• Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9(8):537–549.
   PubMed Web of Science ®Google Scholar
• Kitanaka C, Sato A, Okada M. JNK signaling in the control of the tumor-initiating capacity associated with cancer Stem Cells. Genes Cancer. 2013;4(9–10):388–396.
   PubMedGoogle Scholar
• Zhou F, Yang Y, Xing D. Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS J. 2011;278(3):403–413.
   PubMed Web of Science ®Google Scholar
• Wei Y, Sinha S, Levine B. Dual role of JNK1-mediated phosphorylation of Bcl-2 in autophagy and apoptosis regulation. Autophagy. 2008;4(7):949–951.
   PubMed Web of Science ®Google Scholar